Program
Due to the ongoing COVID-19 pandemic, the 6th Global Forum on TB Vaccines was held as a fully virtual event over four days, from 22 - 25 February 2022. The 6th Global Forum program included plenary sessions, oral abstract sessions, and poster sessions covering the full range of TB vaccine research and development.
Presentations and posters have been posted in the session details below, where permission was granted by the presenters.
Click here to to view the Abstract Book.
Click here to read the meeting report, published in Vaccine: X
AGENDA
Tuesday 22 February 2022
14:30 - 16:00
OPENING SESSION
Session Chairs: David Lewinsohn, Stop TB Partnership Working Group on New TB Vaccines (USA) | Olivier Neyrolles, IPBS [CNRS-Universite Toulouse III] (France)
Welcome and Official Opening
Frédérique Vidal
French Minister for Higher Education, Research and Innovation (France)
Opening Remarks from the WHO Director-General
Tedros Adhanom Ghebreyesus (video)
Director-General, World Health Organization (Switzerland)
Keynote Presentation: Microbes without borders: tensions on our public health paradigm
Philippe Sansonetti
Emeritus Professor, Institut Pasteur and College de France
Keynote Presentation: NIAID TB Vaccine Research - An Update
Anthony S. Fauci
Director, National Institute of Allergy and Infectious Disease, National Institutes of Health (USA)
Opening Remarks
- Jean-Eric Paquet (video)
Director-General, DG Research and Innovation, European Commission (EU) - Carole Nawina Nyirenda (video)
Executive Director, CITAMPlus (Zambia) - Tereza Kasaeva (video)
Director, Global TB Programme, World Health Organization (Switzerland) - Maria Rosario Singh-Vergeire
Undersecretary of Health, Department of Health (Philippines)
16:00 - 16:30
BREAK
16:30 - 17:30
PLENARY: ACCESS AND IMPLEMENTATION OF NEW TB VACCINES
Session Chairs: Alejandro Cravioto, Universidad Nacional Autónoma de México and WHO Strategic Advisory Group of Experts on Immunization (Mexico) | Salome Charalambous, Aurum Institute (South Africa)
Speakers
- Marco Caveleri, European Medicines Agency (EU)
- Birgitte Giersing, World Health Organization (Switzerland)
- Puck Pelzer, KNCV Tuberculosis Foundation (Netherlands)
- Bertrand Kampoer, DRAF TB (Cameroon)
- Maureen Kimenye, Directorate of Public Health, Ministry of Health (Kenya)
- Mukta Sharma, WHO South-East Asia Regional Office (India)
18:00 - 19:00
SPONSORED SESSION: FOLLOW THE EPI: FINDING TB PREVALENT POPULATIONS TO GUIDE PROTOCOL DESIGN
Speakers:
- Ghiorghis Belai, FHI Clinical (Kenya)
- Falgunee K. Parekh, Scientific Expert (USA)
- Jon "Ben" Woods, Scientific Expert (USA)
Sponsored and organized by FHI Clinical
Wednesday 23 FEBRUARY 2022
12:30 - 14:00
POSTER VIEWING
The DCIR/LRP1 axis in myeloid cells: A new target in immunity to tuberculosis?
Tamara Sneperger, IPBS, CNRS (France)
Extracellular vesicles released during Mycobacterium tuberculosis infection: bacterial lipid content and roles in host-pathogen interactions
Emilie Layre, IPBS, CNRS (France)
Blood RNA signatures of the adjunctive administration of cyclooxygenase-2-inhibitor (Etericoxib) or therapeutic vaccine candidate (H56:IC31) in TB disease
Noelia Alonso-Rodriguez, Oslo University Hospital (Norway)
Mucosal vaccination with MTBVAC displays improved induction of trained immunity and broadened local adaptive immune signatures (poster)
Michel Vierboom, BPRC (Netherlands)
Mycobacterium tuberculosis genetic features associated with pulmonary tuberculosis severity (poster)
Charlotte Genestet, Centre International de Recherche en Infectiologie [CIRI], Hospices Civils de Lyon (France)
Comparison of three methods of Mycobacterium tuberculosis complex spoligotype determination for clinical isolates (poster)
Charlotte Genestet, Centre International de Recherche en Infectiologie [CIRI], Hospices Civils de Lyon (France)
Exploring different routes of Vaccination against tuberculosis with parental and recombinant BCG vaccines in murine models
Fadel Sayes, Institute Pasteur (France)
Diet and hyperglycaemia affect vaccine immunogenicity and efficacy in mice (poster)
Elena Stylianou, University of Oxford (UK)
An adjuvant system based on a mesoporous silica particle with a mycobacterial surface lipid bilayer (poster)
Carlos M. Valdemar-Aguilar, Universidad National Autonoma de Mexico (Mexico)
PPM, a potential candidate for RNA vaccine to prevent active TB disease
Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia)
The evaluation of a new recombinant BCG vaccine in cynomolgus macaque model
Natsuko Yamakawa (Japan)
BCG-primed HEHR/CIA09A boosted vaccination mediated improved protection against hypervirulent Mycobacterium tuberculosis strain M2 in mice by eliciting antigen-specific Th1 and Th17 responses
Kee Woong Kwon, Yonsei University (South Korea)
Pulmonary immunity and durable protection induced by the multiantigenic subunit vaccine candidate composed of Rv0351/Rv3628 against the hypervirulent Mycobacterium tuberculosis strain K
Kee Woong Kwon, Yonsei University (South Korea)
Deciphering lysosomal enzymatic activities involved in the processing of mycobacterial antigenic glycolipids
Sonia Belkai, IPBS, CNRS (France)
Development of Novel Autophagy-Prone BCG Strains as Live Vaccines
Isabelle Vergne, IPBS, CNRS (France)
A tractable and accessible method for generating human Alveolar Macrophage Like (AML) cells in vitro: a new breakthrough in lung biology
Susanta Pahari, Texas Biomedical Research Institute (USA)
Safety and reactogenicity of MTBVAC and BCG vaccines in South African adults
Angelique Luabeya Kany Kany, SATVI (South Africa)
Influence of aerosol delivered BCG vaccination on immunological and disease parameters following SARS-CoV-2 challenge in rhesus macaques
Laura Sibley, UK Health Security Agency (UK)
14:00 - 14:30
BREAK
14:30 - 16:00
PLENARY: NEW HORIZONS FOR TB VACCINE R&D
Session Co-Chairs: Yazdan Yazdanpanah, ANRS and I3M Inserm (France) | Luciana Leite, Instituto Butantan (Brazil)
Systems immunomonitoring to support development of new treatments and vaccines for TB (presentation)
Darragh Duffy, Institut Pasteur (France)
What we can learn from the NHP model: Immunology of pre-granulomatous TB infection (presentation)
Louis Picker, Oregon Health & Science University (USA)
Early innate responses to Mtb in the lung
Katrin Mayer-Barber, National Institute of Allergy and Infectious Diseases, NIH (USA)
State of the field: TB vaccine clinical research (presentation)
Mark Hatherill, South African Tuberculosis Vaccine Initiative (South Africa)
Community Perspective
Ashna Ashesh, Survivors Against TB (India)
16:00 - 16:30
BREAK
16:30 - 18:00
ORAL ABSTRACT SESSION: Recognizing the infected cell
Session Co-Chairs: Simone Joosten, Leiden University Medical Center (Netherlands)| Sara Suliman, University of California San Francisco (USA)
Dissecting HLA-E-restricted T-cell responses against Mtb as future targets for vaccination (presentation)
Linda Voogd, Leiden University Medical Centre (Netherlands)
Human memory CD4+ T cells that directly recognize macrophages infected with Mycobacterium tuberculosis are a distinct and smaller subset of those that are antigen-specific
Stephen Carpenter, Case Western Reserve University (USA)
Peripheral blood Mtb-specific T cell frequency and phenotype correlates of TB disease progression
Virginie Rozot, South African Tuberculosis Vaccine Initiative (South Africa)
Characterising the BCG-induced antibody response for M.tb antigen discovery and vaccine development
Rachel Tanner, University of Oxford (United Kingdom)
Identification of M. tuberculosis antigens that induce dominant IL-17 responses during human infection (presentation)
Paul Ogongo, University of California San Francisco (USA)
16:30 - 18:00
ORAL ABSTRACT SESSION: MUCOSAL CONTROL OF MTB
Session Co-Chairs: Steffen Stenger, University Hospital Ulm (Germany) | Elena Stylianou, University of Oxford (UK)
Pulmonary BCG induces long-term activation of lung resident macrophages which contribute to protection against tuberculosis (presentation)
Nacho Aguilo, University of Zaragoza (Spain)
Maturation of iBALT can be mediated by vaccination and serve as backdoor for T cells to the Mycobacterium tuberculosis (Mtb) infected lung (presentation)
Thomas Lindenstrøm, Statens Serum Institut (Denmark)
Mucosal revaccination after intradermal BCG prevents TB disease in rhesus macaques
Frank Verreck, Biomedical Primate Research Centre (Netherlands)
Listeria-vectored vaccine expressing multiple Mycobacterium tuberculosis immunoprotective antigens provides potent protective immunity against aerosol challenge with virulent Mycobacterium tuberculosis in mouse and guinea pig models
Marcus Horwitz, University of California Los Angeles (USA)
Balance between protection and pathogenic response to aerosol challenge with Mycobacterium tuberculosis (Mtb) in mice vaccinated with TriFu64, a fusion consisting of three Mtb antigens (presentation)
Sadaf Sulman, University of the Punjab (Pakistan)
Non-tuberculous mycobacterial mucosal-induced immune response has an enhanced protective effect on BCG's efficacy against Mycobacterium tuberculosis infection (presentation)
Marcela Henao-Tamayo, Colorado State University (USA)
18:00 - 18:30
BREAK
18:30 - 19:30
EARLY CAREER RESEARCHER NETWORKING SESSION
The theme for the networking and discussion session is: Challenges for networking/ opportunities for jobs in TB - What would it take for you to make a career in TB? This networking session is open to all Global Forum participants who want to support early career researchers.
Organized by the Stop TB Partnership Working Group on New TB Vaccines Early Career Researcher Network.
THURSDAY 24 FEBRUARY 2022
11:45 - 12:15
SPECIAL SESSION: INTERNATIONAL COLLABORATION IN COMBATTING INFECTIOUS DISEASES: STRENGTHENING TIES BETWEEN FRANCE AND INDIA
Session Moderator: Srini Kaveri, Director, CNRS Office in India
Speakers:
- Antoine Petit, Chairman and CEO, French National Centre for Scientific Research (CNRS) (France)
- Rajesh Gokhale, Secretary, Department for Biotechnology (DBT), Ministry of Science & Technology (India)
- Stewart Cole, President, Institute Pasteur (France)
- Shekhar C. Mande, Director General, Council of Scientific & Industrial Research (CSIR), Ministry of Science & Technology (India)
This session is organized by CNRS
12:30 - 14:00
ORAL ABSTRACT SESSION: CORRELATES OF PROTECTION AND DISEASE
Session Co-Chairs: Patricia Darrah, National Institutes of Health (USA) | Ruchi Jain Day, Birla Institute of Technology & Sciences (India)
Efficacy of RUTI immunotherapy against active TB in a mouse model challenges the Koch Phenomenon (presentation)
Pere-Joan Cardona, Institute of Recerca "Germans Trias i Pujol" (Spain)
Role of macrophages in HIV-1/M.tuberculosis co-infection (presentation)
Christel Verollet, IPBS (CNRS-UT3), Inserm (France)
Guinea pig PIM-specific, CD1-restricted T cells contribute to granuloma integrity and immune protection against virulent M. tuberculosis
Max Bastian, Frierich-Loeffler-Institut (Germany)
Development of a lung-orientated human infection / antigenic challenge model using live BCG and PPD to gain insights into TB immunopathogenesis
Anil Pooran, University of Cape Town Lung Institute (South Africa)
Influenza virus exposure decreases host derived protection against Mycobacterium tuberculosis infection in ferrets (presentation)
Tuhina Gupta, University of Georgia (USA)
ORAL ABSTRACT SESSION: CLINICAL RESEARCH AND EPIDEMIOLOGY
Session Co-Chairs: Alex Schmidt, Gates Medical Research Institute (USA) | Monde Muyoyeta, Centre for Infectious Disease Research in Zambia (Zambia)
Safety and immunogenicity of an adenovirus-vectored tuberculosis vaccine delivered via inhaled aerosol to healthy humans: A dose and route comparison phase 1 study (presentation)
Fiona Smaill, McMaster University (Canada)
Safety and immunogenicity of the aerosol administered tuberculosis vaccine ChAdOx1-85A (presentation)
Helen McShane, University of Oxford (UK)
A Phase 2a randomized, double-blind, dose-defining trial of MTBVAC compared to BCG in newborns living in a tuberculosis endemic region (presentation)
Michele Tameris, South African Tuberculosis Vaccine Initiative (South Africa)
Therapeutic vaccination in tuberculosis: Results from a phase I/II randomized clinical trial of H56:IC31 and adjunctive Cyclooxygenase-2-inhibitor treatment (presentation)
Anne Ma Dyrhol-Riise, Oslo University Hospital (Norway)
Cytomegalovirus Acquisition in Infancy and the Risk of Tuberculosis Disease in Childhood: A Longitudinal Birth Cohort in Cape Town, South Africa (presentation)
Leonardo Martinez, Boston University (USA)
Improving equity in clinical trials using biosurveillance methodology (presentation)
Ghiorghis Belai, FHI Clinical (Kenya)
14:00 - 14:30
BREAK
14:30 - 16:00
PLENARY: RETOOLING THE IMMUNE RESPONSE TO TB
Session Co-Chairs: Vinay Nandicoori, Council of Scientific & Industrial Research (India) | Anca Dorhoi, Friedrich-Loeffler-Institut (Germany)
A new liposomal adjuvant induces robust Th1/Th17 memory and increased mucosal recall responses in non-human primates
Rasmus Mortensen, Statens Serum Institut (Denmark)
Lentiviral Vectors Leveraged to induce CD4+ T cells against Mycobacterium tuberculosis antigens: Towards a booster against tuberculosis
Laleh Majlessi, Insitut Pasteur (France)
Collaborative Cross mice: a new preclinical model for vaccine development
Samuel Behar, University of Massachusetts Chan Medical School (USA)
DURTy business: Are unconventional lymphocytes important for TB immunity in humans and can we harness them?
Al Leslie, Africa Health Research Institute (South Africa)
Targeting immune evasion for effective TB vaccine design
Baoxue Ge, Shanghai Pulmonary Hospital, Tongji University School of Medicine (China)
Community Perspective
Leonid Lecca, Socias en Salud (Peru)
16:00 - 16:30
BREAK
16:30 - 18:00
POSTER VIEWING AND DISCUSSION
Modeling and Advocacy for Impact
Reducing Delay in Pulmonary Tuberculosis diagnosis by Engaging Informal Healthcare Providers; A Comparative Analysis Between A Semi Rural and an Urban Setting (poster)
Sylvie Kwedi, University of Yaounde (Cameroon)
Quantifying the potential health impacts of adolescent / adult vaccination with M72/AS01E and BCG revaccination-like vaccines in India
Rebecca Clark, London School of Hygiene and Tropical Medicine (UK)
Estimating the potential public health impact of new tuberculosis vaccines in South Africa
Christinah Mukandavire, London School of Hygiene & Tropical Medicine
European commitments to TB R&D investments: Promises made to be broken (poster)
Sarah Steingruber, Treatment Action Group (Germany)
CORRELATES
Identifying immune correlates for BCG-mediated protection in genetically diverse Collaborative Cross (poster)
Rocky Lai, University of Massachusetts (USA)
T cell responses to Mycobacterium tuberculosis variable antigens (poster)
Zachary Howard, University of California San Francisco (USA)
MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies.
Andrew White, UK Health Security Agency (UK)
Host immune correlates of disease persistence in tuberculosis
Shaifali Tyagi, THSTI (India)
FRIDAY 25 FEBRUARY 2022
12:30 - 14:00
PLENARY: ISSUES IN CLINICAL RESEARCH AND DEVELOPMENT
Session Co-Chairs: Michael Makanga, European & Developing Countries Clinical Trials Partnership (Netherlands) | Ann Ginsberg, Bill & Melinda Gates Foundation (USA)
Roadmap for developing TB vaccines in people living with HIV (presentation)
Gavin Churchyard, Aurum Institute (South Africa)
Assessing non-specific effects of a new TB vaccine during clinical development (presentation) Bernard Fritzell, Independent Consultant (France)
Impact of TPT on clinical trial design
Molebogeng Rangaka, University College London (UK)
Engaging communities in TB clinical trials: Lessons learnt from Mbeya, Tanzania
Doreen Pamba, NIMR-Mbeya Medial Research Center (Tanzania)
Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India (presentation)
Matthew Quaife, London School of Hygiene and Tropical Medicine (United Kingdom)
Community Perspective
Patrick Agbassi, Global TB Community Advisory Board (Ivory Coast)
14:00 - 14:30
Break
14:30 - 15:30
PLENARY: RAISING SUPPORT FOR TB VACCINES AS A CENTRAL COMPONENT IN THE GLOBAL HEALTH AGENDA
Session Co-Chairs: Lucica Ditiu, Stop TB Partnership (Switzerland) | Patrick Bertrand, Global Health Advocates (France)
Panelists
- Stephanie Seydoux, French Global Health Ambassador (France)
- Barbara Kerstiens, European Commission (Brussels)
- Rajinder Kumar Suri, Developing Countries Vaccine Manufacturers Network (India)
- Rhea Lobo, Board Member (Alt) - Stop TB Partnership (Denmark)
- Christopher Kalila, Member of Parliament and Global TB Caucus (Zambia)
15:30 - 16:00
CLOSING SESSION
Session Co-Chairs: Mark Feinberg, IAVI (USA) | Nick Drager, TBVI (Netherlands)
Closing Remarks
- Olivier Veran
Minister for Solidarity and Health, France - Budi G. Sadikin
Minister of Health, Indonesia - Marisol Touraine
Chair of the Executive Board, Unitaid; Former French Minister of Health (France) - Seth Berkley
CEO, Gavi, the Vaccine Alliance (Switzerland) - Trevor Mundel (video)
President, Global Health, Bill & Melinda Gates Foundation (USA)